Soleno Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	285.01	190.41	-	-	-	-
Revenue Growth	-	-	-	-	-	-
Cost of Revenue	3.9	2.7	-	-	-	-
Gross Profit	281.11	187.71	-	-	-	-
Selling, General & Admin	153.24	132.13	105.86	13.48	9.84	10.81
Research & Development	38.38	40.63	78.57	25.19	15.27	21.45
Operating Expenses	191.62	172.76	184.43	38.67	25.11	32.26
Operating Income	89.49	14.95	-184.43	-38.67	-25.11	-32.26
Interest Expense	-5.41	-5.48	-0.23	-	-	-
Interest & Investment Income	18.55	16.95	12.05	2.58	0.3	0.11
Other Non Operating Income (Expenses)	-	-	-	-0.18	0.03	0.51
EBT Excluding Unusual Items	102.63	26.43	-172.61	-36.27	-24.78	-31.64
Other Unusual Items	-3.05	-5.54	-3.24	-2.71	0.71	0.73
Pretax Income	99.58	20.89	-175.85	-38.99	-24.07	-30.91
Income Tax Expense	3.54	-	-	-	-	-
Earnings From Continuing Operations	96.04	20.89	-175.85	-38.99	-24.07	-30.91
Net Income	96.04	20.89	-175.85	-38.99	-24.07	-30.91
Preferred Dividends & Other Adjustments	0.42	0.42	-	-	-	-
Net Income to Common	95.63	20.48	-175.85	-38.99	-24.07	-30.91
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	52	51	40	16	8	5
Shares Outstanding (Diluted)	54	52	40	16	8	5
Shares Change	26.81%	30.39%	143.61%	96.40%	57.90%	27.39%
EPS (Basic)	1.83	0.40	-4.38	-2.36	-2.87	-5.81
EPS (Diluted)	1.77	0.39	-4.38	-2.36	-2.87	-5.81
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	105.42	46.73	-69.31	-24.94	-20.79	-27.79
Free Cash Flow Per Share	1.95	0.89	-1.73	-1.51	-2.48	-5.23
Gross Margin	98.63%	98.58%	-	-	-	-
Operating Margin	31.40%	7.85%	-	-	-	-
Profit Margin	33.55%	10.75%	-	-	-	-
Free Cash Flow Margin	36.99%	24.54%	-	-	-	-
EBITDA	91.52	16.97	-182.44	-36.71	-23.15	-30.3
EBITDA Margin	32.11%	8.91%	-	-	-	-
D&A For EBITDA	2.03	2.02	1.99	1.96	1.96	1.96
EBIT	89.49	14.95	-184.43	-38.67	-25.11	-32.26
EBIT Margin	31.40%	7.85%	-	-	-	-

SEC Filings: 10-K · 10-Q